Scorpius Holdings, Inc. Announces Pricing of Public Offering
2024年8月16日 - 10:50PM
Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the
“Company”), an integrated contract development and manufacturing
organization (CDMO), today announced the new pricing of an
underwritten public offering of 12,500,000 shares of common stock
(or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof).
Each share of common stock (or Pre-Funded Warrant) is being offered
at a public offering price of $1.00 per share (inclusive of the
Pre-Funded Warrant exercise price). The gross proceeds to the
Company from the offering are expected to be approximately
$12,500,000, before deducting underwriting discounts and offering
expenses. In addition, the Company has granted the underwriters a
45-day option to purchase up to an additional 1,875,000 shares of
common stock and/or Pre-Funded Warrants solely to cover
over-allotments, if any. As previously announced, the Company had
terminated the pricing of its underwritten public offering that it
had announced on August 6, 2024. Subsequently, the Company
requested, and the NYSE American approved, a financial viability
exception to the NYSE American stockholder approval rules that
would allow the Company to proceed with the closing of the
underwritten public offering upon the terms set forth above.
The offering is expected to close on August 19,
2024, subject to satisfaction of customary closing conditions and
trading of the Company’s common stock on the NYSE American is
expected to resume that same day.
The Company intends to use the net proceeds of
the offering to fund working capital and for general corporate
purposes.
ThinkEquity is acting as sole book-running
manager for the offering.
A registration statement on Form S-1 (File No.
333-280887), as amended, including a preliminary prospectus,
relating to the securities being offered was filed with the
Securities and Exchange Commission (“SEC”) and became effective on
August 6, 2024. This offering is being made only by means of a
prospectus. Copies of the final prospectus, when available, may be
obtained from ThinkEquity, 17 State Street, 41st Floor, New York,
New York 10004. The final prospectus will be filed with the SEC and
will be available on the SEC’s website located
at http://www.sec.gov.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Scorpius Holdings,
Inc.Scorpius Holdings Inc. is an integrated large molecule
contract development and manufacturing organization (CDMO) focused
on rapidly advancing biologic and cell therapy programs to the
clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking StatementsThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions and include statements regarding the timing and
completion of the proposed offering, the timing that trading will
resume and the intended use of proceeds. Important factors that
could cause actual results to differ materially from current
expectations include, among others, the ability to complete the
proposed offering, and other factors described in the Company’s
annual report on Form 10-K for the year ended December 31, 2023,
subsequent quarterly report on Form 10-Q and any other filings the
Company makes with the SEC. The information in this presentation is
provided only as of the date presented, and the Company undertakes
no obligation to update any forward-looking statements contained in
this press release on account of new information, future events, or
otherwise, except as required by law.
For Investor Relations Inquiries:
David Waldman+1
(919)-289-4017investorrelations@nighthawkbio.com
Scorpius (AMEX:SCPX)
過去 株価チャート
から 7 2024 まで 8 2024
Scorpius (AMEX:SCPX)
過去 株価チャート
から 8 2023 まで 8 2024